# Wake Robin Validation Comparison Report

*Generated: 2026-01-14 11:08:47*

---

## Enhancement: Clinical Coverage Expansion
- **Baseline**: 13% clinical coverage (41/316 tickers)
- **Enhanced**: 75%+ clinical coverage (238/316 tickers)
- **Method**: Expanded ticker -> sponsor name mapping

## Validation Status

- **Total Test Periods**: 7
- **Baseline Complete**: 7 [DONE]
- **Enhanced Complete**: 7
- **Pending**: 0

## Quarter-by-Quarter Comparison

| Quarter | Screen Date | Q1-Q5 Spread (Before) | Q1-Q5 Spread (After) | Change | Q1 Alpha (Before) | Q1 Alpha (After) | Change |
|---------|-------------|------------------------|----------------------|--------|-------------------|------------------|--------|
| 2023-Q1 | 2023-01-15 | +8.66% | +13.60% | [UP] +4.94% | +12.18% | +16.81% | [UP] +4.63% |
| 2023-Q2 | 2023-04-15 | +3.79% | +18.90% | [UP] +15.11% | +7.66% | +5.95% | [DOWN] -1.71% |
| 2023-Q3 | 2023-07-15 | +12.97% | +9.71% | [DOWN] -3.26% | +5.29% | +3.73% | [DOWN] -1.56% |
| 2023-Q4 | 2023-10-15 | +18.43% | +57.87% | [UP] +39.44% | +12.58% | +16.67% | [UP] +4.09% |
| 2024-Q1 | 2024-01-15 | +13.19% | +9.65% | [DOWN] -3.54% | +19.21% | +4.93% | [DOWN] -14.28% |
| 2024-Q2 | 2024-04-15 | -14.53% | -4.89% | [UP] +9.64% | -2.54% | +2.28% | [UP] +4.82% |
| 2024-Q3 | 2024-07-15 | +22.62% | +7.95% | [DOWN] -14.67% | +29.57% | +14.43% | [DOWN] -15.14% |

## Aggregate Performance

### Average Q1-Q5 Spread
- **Before**: +9.30%
- **After**: +16.11%
- **Improvement**: +6.81% (+73.2%)

### Average Alpha
- **Before**: +11.99%
- **After**: +9.26%
- **Improvement**: -2.73% (-22.8%)

### Success Rate (Positive Spreads)
- **Before**: 6/7 (85.7%)
- **After**: 6/7 (85.7%)

## Improvements by Quarter

### Q1-Q5 Spread Changes:
- **2023-Q4**: +18.43% -> +57.87% (*+39.44% improved*)
- **2023-Q2**: +3.79% -> +18.90% (*+15.11% improved*)
- **2024-Q2**: -14.53% -> -4.89% (*+9.64% improved*)
- **2023-Q1**: +8.66% -> +13.60% (*+4.94% improved*)
- **2023-Q3**: +12.97% -> +9.71% (*-3.26% decreased*)
- **2024-Q1**: +13.19% -> +9.65% (*-3.54% decreased*)
- **2024-Q3**: +22.62% -> +7.95% (*-14.67% decreased*)